PTK787/ZK222584 and RAD001 for Patients With Advanced Solid Tumors
OBJECTIVES:
Primary
- Determine the maximum tolerated dose (MTD) of vatalanib and everolimus in patients with
advanced solid tumors.
- Determine the safety and tolerability of vatalanib and everolimus in patients with
advanced solid tumors.
- Evaluate the safety and tolerability of vatalanib and everolimus at the MTD in patients
with metastatic renal cell carcinoma (RCC).
Secondary
- Describe the non dose-limiting toxic effects associated with vatalanib and everolimus.
- Describe the pharmacokinetics of vatalanib and everolimus in patients with advanced
solid tumors.
- Determine the functional extent of mTOR inhibition by changes in the phosphorylation
status of S6K protein in peripheral blood mononuclear cells in patients treated with
vatalanib and everolimus.
- Describe any clinical responses seen in patients with metastatic RCC in a
dose-expansion cohort treated at the MTD.
- Observe overall survival of RCC patients treated with vatalanib and everolimus.
- Determine the time to progression of patients with RCC treated with vatalanib and
everolimus.
OUTLINE: This is a phase I dose-escalation study followed by a phase Ib study.
- Phase I (solid tumors): Patients receive oral vatalanib on days 1-28 and oral
everolimus on days 15-28 during course 1 and on days 1-28 during all subsequent
courses. Treatment repeats every 28 days for up to 12 courses in the absence of disease
progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of vatalanib and everolimus until the
maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at
which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
- Phase Ib (renal cell carcinoma only): Patients receive oral vatalanib and oral
everolimus at the MTD on days 1-28. Treatment repeats every 28 days for up to 12
courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed every 6 months.
PROJECTED ACCRUAL: A total of 44 patients will be accrued for this study.
Interventional
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Maximum tolerated dose (MTD) of vatalanib and everolimus
Patients were evaluated on Day 1,14 and 28 for dose limiting toxicities
Day 1 - 28
Yes
Daniel J. George, MD
Principal Investigator
Duke Cancer Institute
United States: Food and Drug Administration
Pro00012347
NCT00303732
December 2004
August 2012
Name | Location |
---|---|
Duke Comprehensive Cancer Center | Durham, North Carolina 27710 |